← ANALYST RATINGS · TIPRANKS
QuidelOrtho (QDEL): analyst forecast and price target
Analyst consensus
Hold1 Buy0 Hold1 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $12.00, the highest $12.00, the lowest $12.00. The average is −7.0% from the last price of $12.91.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI Anthropic Medical - SpecialtiesAnthropic Opus-4.6 | TipRanks - Anthropic | $13.50 → $13.00−3.7% | Sell | +0.7% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Google Medical - SpecialtiesGemini 3.1Pro | TipRanks - Google | $14.00 → $13.50−3.6% | Hold | +4.6% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI xAi Medical - SpecialtiesxAI Grok-4 | TipRanks - xAI | $10.50 → $14.00+33.3% | Hold | +8.4% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| AI DeepSeek Medical - SpecialtiesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $10.50 → $13.50+28.6% | Hold | +4.6% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| AI OpenAI Medical - SpecialtiesOpenAI 5.2 | TipRanks - OpenAI | $10.50 → $14.00+33.3% | Hold | +8.4% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| AI PerPlexity Medical - SpecialtiesPerPlexity SonarPro | TipRanks - PerPlexity | $13.00 → $13.50+3.8% | Hold | +4.6% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $12.00 | Sell | −7.0% | Reiterated | 14.10.26on TipRanks 06:35 | −0.6%next day 0.0% | ↗ |
| William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% | Craig-Hallum | — | Buy | — | Reiterated | 24.09.26on TipRanks 09:10 | +3.5%next day +1.8% · 5 days −2.5% | ↗ |
| Patrick B Donnelly★★★★★★★★★★#2106 · hits 54% · avg +6.0% | Citi | $13.00 → $18.00+38.5% | Hold | +39.4% | Reiterated | 08.07.26on TipRanks 06:50 | +1.8%next day +0.3% · 5 days +4.4% | ↗ |
| Lu Li★★★★★★★★★★#5185 · hits 80% · avg +11.8% | UBS | $17.00 → $12.00−29.4% | Hold | −7.0% | Assigned | 07.05.26on TipRanks 08:06 | −1.4%next day −0.5% · 5 days +3.5% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $12.50 | Hold | −3.2% | Downgrade | 07.05.26on TipRanks 05:31 | −1.4%next day −0.5% · 5 days +3.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering QuidelOrtho
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $15.00 at a price of $10.54 (+42.3%); now: $12.00 at $12.91 (−7.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 1 | 0 | 1 | 1 |
| Hold | 4 | 4 | 5 | 2 | 2 | 0 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.20 (from $0.18 to $0.23). Last quarter: $0.13.
Sales
Next quarter’s sales estimate — $628M (from $615M to $635M). Last quarter: $630M.
Best top-analyst consensus in the sector · Healthcare
About QuidelOrtho
- CEO: Brian J. Blaser
- Employees: 6,500
- 9975 Summers Ridge Road, San Diego, CA, 92121, US
- www.quidelortho.com
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Data from the stock’s TipRanks forecast page, read 143 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗